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Background: Survival of oropharyngeal squamous cell carcinoma (OSCC) patients depends on the risk and environmental factors, tumor 
biology, achievements in diagnostics and treatment approaches. Aim: To perform a survival analysis of the patients with OSCC treated 
over a 10-year period in a single hospital in Latvia linking these data to histopathological findings, risk factors and received therapy. 
Materials and Methods: The main outcome measures were overall and disease-specific survival (OS and DS) along with histopathology 
analysis. Results: Kaplan – Meier survival analysis showed better survival for females, younger patients lacking bad habits, operated 
and received radiotherapy, with lower T grade and disease stage. Cox regression showed diminished early death risk in patients with 
lower T grade, no regional metastases (N0) and bad habits, operated and received radiotherapy. A vast majority of tumors were localized 
in palatine tonsils and the base of the tongue. The localization did not correlate with mean survival time/survival. Lower OS (p = 0.03) 
and DS (p = 0.026) were estimated for patients with pharyngeal wall and tonsillar involvement compared to tumors localized in the soft 
palate. A histological variant of tumor seemed irrelevant estimating OS and DS, whereas therapeutic modalities significantly affected 
survival. Conclusions: OSCC patients with lower T grade, N0 status, lacking bad habits, and surgically treated had better survival.
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The oropharynx is one of the most common lo-
calizations for malignant neoplasms in the head and 
neck region. The GLOBOCAN data (2012) confirm over 
140,000 new cases of pharyngeal cancer worldwide 
and age-standardized incidence of 1.9 per 100,000, 
whereas in Europe — about 34,000 new cases and 
age-standardized incidence of 2.9 [1].
Histopathologically, most malignancies found in the 
oropharynx (~ 90%) are squamous cell carcinoma (SCC) 
[2]. Although SCC of the oropharynx is diagnosed pre-
dominantly in people over the age of 45 years, some 
studies suggest an increased incidence of the disease 
in people less than 45 years of age, over the past 
20–30 years [3]. Commonly, these tumors arise from 
certain regions — palatine tonsils, the base of the tongue, 
soft palate, and posterior pharyngeal wall and in greater 
than 60% of patients present with cervical lymph node 
involvement and 10–15% with distant metastases [2]. 
It has been found that the rates of lymph node metastasis 
vary considerably by localization with tumors of the tonsil 
and base of the tongue more likely presented with posi-
tive nodes than tumors of the soft palate and pharyngeal 
wall [4]. Approximately 60% of oropharyngeal SCCs 
(OSCC) have been found to be moderately differentiated, 
20% well-differentiated, and 20% poorly differentiated 
[5]. Other tumors, namely minor salivary tumors (ad-
enomas/adenocarcinomas), primary lymphoid tumors, 
undifferentiated tumors, various sarcomas, and mixed 
neoplasms also present in the oropharynx [6], and clini-
copathological findings vary from country to country [7].
Major etiological and predisposing factors for this 
neoplasm include smoking and drinking habits, and sev-
eral other factors such as human papillomavirus (HPV) 
and Candida infections, nutritional deficiencies and 
genetic predisposition [7–10]. Furthermore, it has been 
demonstrated that the carcinogenic effects of both 
alcohol and tobacco smoke on the oropharynx appear 
to function in dose-dependent manners [6], and increase 
6–7-fold in individuals overusing tobacco or alcohol and 
as much as 15-fold with those who both smoke and drink 
alcohol [11].
Analysis of survival rates in the case of SCC reveals 
greatly varying data due to the variability of the obser-
vation period, patients’ features, surgeons’ expertise, 
percentage of starting tumors compared with advanced 
ones, quality of radiotherapy (RT), and the use of adjuvant 
treatments [12]. Pathologically, the significant predictors 
of 5-year disease-free survival proposed very recently 
by analyzing invasive tumor patterns of SCC were defined 
as the mode of invasion, worst pattern of invasion, and 
tumor budding as well as lymphovascular and perineural 
invasion [13]. The 5-year survival rate has been shown 
to range from 58% up to 94% [14]. A decrease in survival 
rate in a long-term follow-up happens mostly due to the 
development of new primary tumors, which have the same 
etiologic factors, and intercurrent deaths often caused 
by the same etiologic factors and by the age of the patients 
[15]. Other studies suggest an improvement in the 5-year 
Submitted: May 4, 2019. 
*Correspondence: E-mail: andrejs.lifsics@gmail.com 
Abbreviations used: ChT — chemotherapy; DS — disease-specific 
survival; H&E — hematoxylin and еosin; HPV — human papillomavirus; 
HR — hazard ratio; KSCC — keratinizing SCC; NKSCC — nonkeratiniz-
ing SCC; OS — overall survival; OSCC — oropharyngeal squamous 




52 Experimental Oncology 42, 51–59, 2020 (March)
overall survival (OS) and disease-specific survival (DS) 
rates during the past decade compared with the previous 
decade even despite older age, more advanced disease 
stage, and a higher rate of distant metastases, presum-
ably due to the recent advances in tumor imaging and 
therapy [12, 14]. The world incidence of OSCC varies and 
estimated differences in the incidence and survival are 
generally related to the distinct risk and socioeconomic 
factors, environmental agents, public health awareness 
and accessibility of health services, as well as advances 
in diagnostics and therapy. Therefore, the aim of this study 
was to perform a survival analysis of the patients with 
OSCC treated over a 10-year period in a single hospital 
in Latvia correlating these data with histopathological find-
ings, disease stage, tumor grade, nodal grade, patients’ 
age and sex, habits (smoking, alcohol abuse), primary 
tumor location, and received therapy.
MATERIALS AND METHODS
We carried out a retrospective study of 247 patients di-
agnosed with OSCC, staged following the TNM classifica-
tion of the International Union against Cancer (6th edition) 
for oropharyngeal carcinoma and treated in Riga Eastern 
Clinical University Hospital Stationary Oncology Centre 
of Latvia between January 1st, 2000 and December 31st, 
2010. Patients are admitted to this hospital from all over the 
country, which has an estimated population of 1.91 million. 
The patients’ data were collected from the Hospital Archive 
and The Centre for Disease Prevention and Control and 
included in the study when the diagnosis of OSCC was 
confirmed histologically. The study was approved by the 
Ethical Committee of Riga Stradins University.
The data collected were processed to calculate the 
overall and disease-specific 3 and 5-year survival rates 
for all patients. The Kaplan — Meier survival analysis was 
used for the estimation of statistical data. Statistical testing 
for differences in unadjusted survival rates was performed 
using the log-rank test. A Cox regression method was used 
to estimate hazard ratio (HR). Age, sex, T stage, N status, 
risk factors (smoking, alcohol abuse), therapy modality 
(RT, surgery (SUR), chemotherapy (ChT), symptomatic 
therapy and combinations of aforementioned, primary 
tumor location, histopathological variant of tumor were 
included as covariates in the survival model. ChT consisted 
of a single-agent regimen with cetuximab or platinum 
medication (cisplatin).
Statistical analysis of correlation of aforementioned 
covariates with survival, and mean OS time after 
diagnosis was performed. We used Pearson’s chi-
squared test or Fisher’s exact test (depending on the 
size of the group) to find out if differences between 
analyzed groups are statistically significant, the value 
of p < 0.05 was considered significant. Cramer’s V was 
used to measure an association between two nominal 
variables. For analysis of the correlation between no-
minal variables and mean survival time after diagnosis 
Kruskal — Wallis test or Mann — Whitney test (depend-
ing on the number of groups) were used.
Formalin-fixed paraffin-embedded OSCC samples 
obtained from all major subsites and sections cut off 
were retrieved from the archival files of the Department 
of Pathology Oncology Centre of Latvia, and pathology 
reports for all tumors were reviewed. Hematoxylin and 
eosin (H&E) stained sections were analyzed, and the 
tumors were classified according to their histologic fea-
tures. Patterning of the invasion at the advancing tumor 
edge, the presence of perineural invasion, and immune 
system response as proposed by Brandwin et al. [16] 
and thereafter commented by the other scientists [17] 
were underestimated in the early years of this retrospec-
tive study. Therefore, the histopathological assessment 
was done not taking into account the revision of surgical 
margins and the evaluation of supplemental tissue. Mi-
crophotographs were obtained using Leitz DMRB bright-
field optics equipped with a digital camera DC 300F.
RESULTS
The retrospective cohort consisted of 247 patients 
with pathologically confirmed OSCC, stage I–IV present-
ed by the following subsites — palatine tonsils (n =110, 
44.52%), base of tongue (n = 76, 30.77%), soft palate 
(n = 20, 8.10%), and posterior pharyngeal wall (n = 41, 
16.60%). Unfortunately, less than one-tenth of the 
cohort presented with stage I and II — 3 (1.22%) and 
19 (7.72%) patients, accordingly, whereas a major por-
tion — 224 (91.6%) revealed advanced disease stage. 
By gender, 8.10% (n = 20) of all reviewed patients were 
female and 91.90% (n = 227) — male. The mean patient 
age was 60 years (range 27–85), median — 60.20 years.
When the patients’ data were collected and summed-
up we found that most of the patients were regular 
smokers (75.95%, n = 180), habitual drinkers (35.19%, 
n = 82) or were exposed to both aforementioned major 
risk factors (31.47%, n = 73). The general characteristics 
of the patients are summarized in Table 1.
Table 1. Characteristics of the patients

















































Alcohol and smoking — n (%): 73 (31.47)
Note: *Unknown for 1 patient; **unknown for 2 patients; ***unknown for 
14 patients; ****unknown for 10 patients.
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Female patients had significantly longer mean sur-
vival time than males, but we found no correlation be-
tween survival and gender (V1 = 0.09, p = 0.25) as well 
as mean survival time and gender (η = 0.17). OS analy-
sis showed better survival for females, but it wasn’t sig-
nificantly different when compared to males (p = 0.06). 
By contrast, DS survival in female patients appeared 
to be significantly better (p = 0.0486).
Additionally, survival was estimated subdividing 
the subjects into three age groups — younger than 
55 years; 55 to 64 years old and older than 65 years. 
There were significantly more deceased patients in the 
subgroup with advanced age when compared to young-
er individuals (p = 0.028). However, no correlation was 
found between both age group and survival (V1 = 0.17), 
and mean survival time (η = 0.16). Kaplan — Meier es-
timates showed a decrease in survival with increasing 
age, but the differences in OS and DS weren’t statisti-
cally significant when all three age groups were consid-
ered (p = 0.092 and p = 0.108). In spite of that, pairwise 
comparisons showed statistically significant differences 
in survival between patients younger than 55 years 
and older than 64 years (p = 0.048). Table 2 deciphers 
a decrease in OS with more advanced age.
There was a moderate correlation between survival 
and disease stage (V1 = 0.32, pχ = 0.0014). Kaplan — 
Meier survival analysis showed almost statistically 
significant (overall comparisons, p = 0.058) OS and 
DS differences according to the disease stage (see 
Table 2). In pairwise comparisons, a statistically 
significant difference in OS between stage I and 
stage II disease (p = 0.139), stage II and stage III 
disease (p = 0.112), stage III and stage IV disease 
(p = 0.104) was not found. Similar observations were 
made in pairwise comparisons between stages in DS.
Mean survival time and the positive outcomes (the 
patient survived) of the disease appeared to decrease 
with higher T grade, and there was a moderate cor-
relation between outcome and T grade (V1 = 0.27), 
whereas no correlation between mean survival time 
and T grade (η = 0.2830). Kaplan — Meier survival 
analysis showed a better OS and DS when lower tumor 
grade (T1–2) was compared to higher tumor (T3–4) 
grade (see Table 2).
There was no correlation between N status and 
mean survival time/survival (outcome). We found 
no statistical difference in OS and DS (p = 0.11 in both 
cases) according to N status (N0 vs N+; see Table 2).
Table 2. Kaplan — Meier analysis of potential prognostic factors for DS, OS
Variable 3-year Kaplan — Meier estimate, % (95% CI) 5-year Kaplan — Meier estimate, % (95% CI)OS DS OS DS











































































































































































0% p < 0.001
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A moderate correlation between smoking and 
survival (V1 = 0.21, Pχ = 1.77 • 10-3) was found, but 
there was no correlation between mean survival 
time and smoking (η = 0.17). Kaplan — Meier sur-
vival analysis showed a statistically higher OS and 
DS in subjects nonsmokers (p < 0.05). There was 
no correlation between alcohol abuse and survival/
mean survival time.
Significantly higher OS was estimated for patients 
who didn’t abuse alcohol (p = 0.03), whereas a de-
crease of the significance was found regarding DS 
(p = 0.08). However, there was a statistically significant 
decline in the OS and DS in the patients’ group who 
smoked and abused alcohol simultaneously (yes vs no) 
(see Table 2, Fig. 1).
OSCC analyzed in the study developed from diffe-
rent subsites, but there was no impact of tumor loca-
tion on mean survival time/survival. Worst OS (p = 0.03) 
and DS (p = 0.026) estimates were found for subjects 
presented with pharyngeal and tonsillar tumors, thus 
opposing estimates for patients presented with tumors 
of the soft palate (see Table 2).
Keratinizing SCC (KSCC) tissue samples showed 
large polygonal squamous cells with distinct cell 
borders and keratin formation revealing a spectrum 
of grades from well-differentiated to poorly differen-
tiated tumors with various degrees of keratinization 
(Fig. 2, 3, 4). Keratin pearls were present. Squamous 
maturation was diffuse even in poorly differentiated 
tumors that lack keratinization. Keratinizing tumor 
samples with abundant eosinophilic cytoplasm were 
often composed in discrete nests and displayed 
nuclear pleomorphism (see Fig. 2 and Fig. 5). The in-
filtrative nests of tumor cells usually were found within 
stroma revealing prominent desmoplasia.
Fig. 1. Kaplan — Meier DS plot according to hazardous habits
Fig. 2. Soft palate region. KSCC (verrucous type) showing folded 
and thickened neoplastic epithelium comprised of large polygo-
nal cells with distinct cell borders and varying degree of eosino-
philia. Nuclei are pleomorphic. H&E, original magnification, ×200
Fig. 3. Base of the tongue. NKSCC. Densely packed mitotically 
active epithelial cells forming the pushing and infiltrating masses 
of carcinoma. H&E, original magnification, ×200
Fig. 4. Palatine tonsil. NKSCC. Nests of tumor cells with ill-
defined borders and necrosis. H&E, original magnification, ×200
Fig. 5. Soft palate region. KSCC. Tumor cells demonstrate nuclear 
pleomorphism, mitotic and apoptotic features. Some tumor cells 
contact the nerve bundle. H&E, original magnification, ×250
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Nonkeratinizing SCC (NKSCC) tumors often 
formed nests, sheets, and cords with well-defined 
borders. These tumors were characterized by relatively 
monomorphic, densely packed, ovoid, and spindle-
shaped basaloid cells with indistinct cell borders. Mi-
totically active tumor cells revealed highly hyperchro-
matic nuclei and high nuclear-to-cytoplasmic ratio.
Although this study did not attempt to distinguish 
HPV driven tumors from those, which are HPV negative, 
we might speculate that KSCC are highly likely HPV 
negative whereas NKSCC highly suggestive of HPV 
association. Usually, these NKSCC formed sheets, 
nests, and cords with sharply defined borders; tumor 
cells displayed basaloid features and peripheral pali-
sading (Fig. 6).
Most of the tumors were KSCC (n = 175, 70.85%), 
19.43% were NKSCC (n = 48), 1.21% — undifferenti-
ated carcinomas (n = 3), 1 (0.4%) — adenosquamous 
carcinoma, for the remainder of tumors keratinization 
pattern wasn’t specified (n = 20, 8.10%). A histological 
variant of tumor seemed irrelevant estimating OS and 
DS (p > 0.05). Furthermore, a correlation between 
histological variant and mean survival time/survival 
was not found.
When recognizing that histological grade based 
on the amount of keratinization is not a consistent 
predictor of clinical behavior we fixed the presence 
of perineural spread, lymphovascular and muscular 
invasion to better understand aggressive behavior 
of the tumor. We found that perineural invasion and 
lymphovascular invasion are frequently observed 
in SCCs causing a decrease of survival (see Fig. 6). 
Additionally, the islands and cords of malignant cells 
infiltrated the underlying skeletal muscle tissue when 
the deeper invasion of the tumor masses took a place 
(Fig. 7).
We found a strong correlation between survival and 
therapy (V1 = 0.32), but no correlation between therapy 
and mean survival time (η = 0.33). There were signifi-
cant OS and DS differences (p < 0.001) between thera-
peutic modalities (Table 2), with better survival in SUR 
and RT+SUR groups. Pairwise comparisons revealed 
significant OS differences only in RT vs RT+SUR, 
RT+SUR vs RT+ChT (cetuximab)+/–SUR groups 
(p < 0.05), and borderline significance in RT vs SUR 
group, showing higher survival in those patients who 
underwent SUR and lowest survival in RT group. 
Similar observations were made performing pairwise 
comparisons between therapy modalities and DS.
Most of the patients didn’t receive SUR as thera-
peutic modality (n = 196), 10 patients had primary 
tumor excision, 28 underwent neck dissection, and 
13 had both, primary tumor excision and neck dis-
section. When suggesting the outcome of the disease 
and the impact of SUR as well as the type of operation 
done, we found that the number of deceased patients 
was much higher when no operation was done (Ta-
ble 3). Furthermore, mean OS time after establishing 
the diagnosis of the disease was significantly longer 
in surgically treated patients; however, the correla-
tion between mean OS time and the aforementioned 
treatment modality was not found. Kaplan — Meier 
analysis showed significant differences in survival 
(OS and DS) depending on whether the patient was 
operated on or not, with a much higher survival rate 
in patients who underwent SUR (p < 0.0001). How-
ever, OS and DS pairwise comparison of SUR type 
didn’t show any significant differences (p = 0.29 for 
OS and p = 0.11 for DS).
Cox regression method was applied in two stages: 
(1) all the factors were analyzed without distinguish-
ing subgroups of each factor (univariate analysis; 
Table 4); and then (2) subgroups of each factor were 
assessed (multivariate analysis, see Table 5). T grade 
(p < 0.00001), N status (p = 0.017) and sex (p = 0.049) 
appeared to have a statistically significant or probable 
impact on the mortality after detection of the disease 
in the common comparison model (see Table 4) (value 
of B is positive). Individually for grade T, the risk of death 
increases by 39% (Exp (B) = 1.39) if T grade increases 
with other values remaining constant. By contrast, the 
risk of death increases by 51% (Exp (B) = 1.51) in case 
of N status, if there is a change from N0 to N + when 
other values remain fixed. Finally, the risk increases 
Fig. 7. Posterior pharyngeal wall. Poorly differentiated SCC. Tu-
mor nests and nodules reveal muscular invasion; lymphoplas-
macytic infiltration. H&E, original magnification, ×250
Fig. 6. Base of the tongue. NKSCC. Nests and cords of tumor 
cells with basaloid features, peripheral palisading, intraluminal 
necrosis, keratocysts. H&E, original magnification, ×100
56 Experimental Oncology 42, 51–59, 2020 (March)
by 70% (Exp (B) = 1.70) within the gender axis (female 
> male). Other features in a particular regression model 
didn’t have a statistically significant impact on the risk 
of earlier death. Cox regression plot for cumulative sur-
vival shows that 50% of patients die before 12 months 
after the diagnosis of cancer (Fig. 8).
It was found that T2 grade, N status, presence 
of one of the hazardous habits (smoking or alcohol 
abuse) and treatment modality — RT+SUR have a sta-
tistically significant impact on the risk of death when 
accounting nine factors and analyzing the HR between 
subgroups of factors (see Table 5). Patients with 
T2 grade tumor have 57% and 77% reduction in the risk 
of early death when compared to patients with T3 and 
T4 grade tumors. Finally, we found that there is a 34% 
reduction in the risk of early death when N0 status 
is compared to N+.
Significantly (p = 0.0467) lower early death risk was 
determined for patients exposed to SUR in combina-
tion with RT (p = 0.002) when compared to other treat-
ment modalities, including RT alone or in combination 
with cetuximab (Fig. 9). When compared to sympto-
matic treatment, RT+SUR therapy has 300% or 3 times 
lower early death risk, but compared to RT+ChT (ce-
tuximab) +/–SUR therapy — 154% or 1.54 times lower 
early death risk. When a combination of two — RT+SUR 
treatment modalities are compared to RT or SUR alone, 
there is 2.02 and 1.27 times greater death hazard es-
timated for RT and SUR, respectively.
Cox regression multivariate analysis showed that 
alcohol abuse and/or smoking significantly increase 
the risk of early death. Results of the Cox proportion 
hazard model are summarized in Tables 4 and 5.
DISCUSSION
We performed a survival analysis of the patients 
with OSCC treated over a 10-year period in a single 
Table 3. Breakdown of patients by type of operation and outcome of the disease
Type of operation N of patients (incidence, %)* Outcome of the disease (therapy)
N of patients 
(incidence, %) Statistical analysis between groups
Primary Tu excision 10
(4.05; 19.61)
Positive (survived) 3 (30.00) All groups Only operations
Negative (deceased) 7 (70.00) Pχ V1 Pχ V1
Neck dissection 28
(11.34; 54.90)
Positive (survived) 5 (18.52) 7.11 x10-6 0.33 0.19 0.26
Negative (deceased) 22 (81.48)
Both 13
(5.26; 25.49)
Positive (survived) 6 (46.15)
Negative (deceased) 7 (53.85)
None 196
(79.35; -)
Positive (survived) 12 (6.25)
Negative (deceased) 180 (93.75)
Note: *Тhe incidence among all patients and the incidence only between operations.
Table 4. Cox proportional hazard, univariate analysis
Variable B P Exp(B) CI 95% Exp(B)
Sex 0.53 4.88 ∙ 10-2 1.70 1 … 2.88
Age groups 0.14 0.14 1.15 0.95 … 1.4
Alcohol abuse and/
or smoking
0.02 0.83 1.02 0.85 … 1.22
T grade 0.33 2.40 ∙ 10-5 1.39 1.2 … 1.63
N status (N0 vs N+) 0.41 1.35 ∙ 10-2 1.51 1.09 … 2.09
Therapy –0.10 0.14 0.90 0.79 … 1.03
Primary tumor location –0.08 0.29 0.92 0.79 … 1.07
Histological variant 0.07 0.36 1.07 0.92 … 1.25
Table 5. Cox proportional hazard model, multivariate analysis
Variables P Exp (B) or HR* CI 95% Exp (B) HR comparing to other groups^
Sex (female > male) 0.11 0.63 0.36 … 1.11
Age group 0.15
<55 years old 0.10 0.70 0.46 … 1.06
55—64 years old 0.08 0.74 0.52 … 1.04
>64 years old (1.00)
Alcohol abuse and/or smoking 0.06
None 0.43 0.84 0.55 … 1.29
1 of aforementioned 0.051 1.42 1 … 2.01
Both (1.00)
T grade 3.51 ∙ 10-2
1 0.13 0.60 0.31 … 1.17 1.06
2 6.72 ∙ 10-3 0.57 0.37 … 0.85
3 0.51 0.89 0.62 … 1.26 1.57
4 (1.00) 1.77
N status (N0 > N+) 1.58 ∙ 10-2 0.66 0.47 … 0.93
Therapy 0.09
RT 0.42 0.67 0.26 … 1.75 2.02
OP 0.20 0.42 0.11 … 1.56 1.27
RT+SUR 4.67 ∙ 10-2 0.33 0.11 … 0.98
RT+ChT (cetuximab) +/–SUR 0.70 0.80 0.26 … 2.44 2.41
RT+ChT (platinum) +/–SUR 0.44 0.51 0.09 … 2.82 1.54
Symptomatic (1.00) 3.00
Primary tumor location 0.55
Palatine tonsil 0.19 1.48 0.82 … 2.64
Base of the tongue 0.37 1.32 0.72 … 2.4
Pharyngeal wall 0.20 1.52 0.79 … 2.92
Soft palate (1.00)
Histological variant 0.73
KSCC 0.78 0.93 0.54 … 1.59
NKSCC 0.90 0.96 0.52 … 1.78
Carcinoma, undifferentiated (Epit) 0.35 1.84 0.51 … 6.67 1.91
SCC, BCN (unspecified) (1.00) 1.04
Note: *HR — hazard ratio-calculation using the last group as a reference; ^calculated for significant groups (bold) against others, taking a significant group 
as a reference.
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hospital in Latvia making attempts to link the data with 
disease stage, tumor stage, patients’ age and sex, 
habits (smoking, alcohol abuse), histopathological 
variant of the tumor, primary tumor localization, and 
received therapy.
We found that two-thirds of the patients (76%) were 
smokers, whereas one third — (35%) had drinking 
problems. Regarding the relevance of habits, our study 
confirmed the independent role of these risk factors in sur-
vival (OS and DS), where smoking seems to play a more 
important role in survival, especially DS. Moreover, the 
combination of these two factors significantly decreases 
survival (DS and OS). Similar evidence has been reported 
previously [18–21]. Furthermore, according to our Cox 
hazard model (multivariate analysis) an early death risk 
is higher when at least one of the risk factors is present.
Our study showed that a vast majority of patients 
were diagnosed in advanced disease stages (III and IV) 
resulting in poorer outcome prognosis. Kaplan — 
Meier estimates of OS and DS for disease stage 
showed worse survival for late disease stages. Our 
investigation revealed that of 247 subjects used in the 
present study, there were only 3 and 19 patients with 
stage I and stage II disease, accordingly. The impor-
tance of early cancer diagnosis and fast referral to the 
specialist has been previously highlighted [22]. Our 
estimations of survival appear to support this.
OSCC is an aggressive tumor commonly diagnosed 
in advance stages and characterized by a high rate 
of lymphatic metastasis [23]. This was also true for our 
study where 68.4% of patients presented with clinically 
positive neck disease (locoregional spread of cancer 
to neck lymph nodes). Furthermore, N+ patients had 
higher early death risk (Cox regression multivariate 
analysis), although there were no significant diffe-
rences in OS and DS.
We found that lower T grade tends to correlate 
with better disease outcome. This statement was 
confirmed by Kaplan — Meier estimates of OS and 
DS, which showed a significant (p < 0.001) decrease 
in survival by T grade revealing the longest survival for 
lower T grades. Nevertheless, it is worth noting that 
our estimates of survival are lower than those demon-
strated in the western hemisphere [24].
Our study showed the worst OS and DS for tumors 
of pharyngeal wall and palatine tonsils, and these data 
partially agree with the literature [6]. In our study, the 
majority of the patients had palatine tonsil and base 
of tongue SCC associated with poorer survival.
In the given study, better OS and DS estimates 
were demonstrated for the surgically treated patients. 
Indeed, it may be argued that there is a selection 
bias in the treatment modalities. The present study 
brought evidence that SUR might have a clear role 
in better disease outcome, and the best outcome 
was demonstrated for the RT+SUR group. We were 
not able to show any significant differences in survival 
based on the type of SUR applied (primary tumor 
excision, neck dissection or both), however, these 
appeared when SUR vs no SUR at all was compared. 
However, we must admit that the numbers of patients 
constituting the study groups we used were unequal 
and not very high. Reviewing the literature, we found 
that surgical treatment has emerged as the necessary 
treatment modality for most patients [25].
Furthermore, other studies have shown a sur-
vival benefit in operated patients, even when stratified 
by HPV status [26–28]. However, controversy in results 
when HPV status was taken into account appears 
to be elucidated [29]. In his study, Münscher et al. 
showed that the HPV status seemed to have no im-
pact on survival [29]. We hope that our observations 
have highlighted the necessity of further studies when 
OSCC outcome is compared in patients with uni- or bi-
lateral neck dissection.
However, there are some studies that state no dif-
ference in long-term survival between uni- and bilateral 
neck dissection in patients with contralateral clinically 
negative neck [30–33].
Gillison et al. in their study have proved the supe-
riority of cisplatin plus RT as opposed to cetuximab 
plus RT in HPV-positive OSCC [34]. Unfortunately, 
we should confirm that cetuximab is the only chemo-
therapeutic agent for the head and neck used in Latvia 
when treating SCC. There is compelling evidence for 
reconsidering the chemoradiotherapy regimen. In this 
study, performing survival analysis of patients with 
OSCC we found that younger patients had lower early 
death risk than older ones. Furthermore, by reviewing 
Fig. 8. Cox regression plot for cumulative survival (overall) accounting 
for all covariates (sex, age group, T grade, N status, alcohol abuse 
and/or smoking, therapy, primary tumor location, histological variant)
Fig. 9. Cox regression plot for cumulative survival. Covari-
ates — sex, age group, T grade, N status, alcohol abuse and/
or smoking, therapy, primary tumor location, histological variant. 
Plot for therapy
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the literature one should note that RT produces the 
long-lasting depression of the immune system and 
makes some OSCC patients more susceptible to tumor 
recurrence and worse survival [35].
Prognostic factors have been recognized to be im-
portant in selecting the appropriate treatment for the 
patient. In the current study, we made attempts to pre-
dict the course of OSCC investigating the possible 
prognostic factors. We found that the patient’s even-
tual outcome is strongly predicted by the T stage, 
therapeutic modality received (RT+SUR), hazardous 
habits (smoking, alcohol abuse), and the presence 
of lymph node metastases. Collectively, these results 
are suggestive of neck dissection necessity, and other 
studies have reported on the effectiveness of ipsila-
teral elective neck dissection in clinically negative 
necks [36–38]. Unfortunately, in our study, data on the 
HPV status were lacking cutting off the evaluation 
of the prognostic value of this factor recommended 
by other scientists [39–44].
In the given study, statistically significant differen-
ces in survival rates estimated for patients with OSCC 
revealing various types of tumor differentiation were 
not found. Unfortunately, completeness of records 
deciphering the differentiation of tumor cells, the 
type of growth (exophytic or endophytic), and the 
presence of perineural invasion were not absolute. 
However, some previous studies have demonstrated 
that endophytic growth, perineural invasion, and 
extracapsular extension of tumor allow suggesting 
on contralateral neck metastasis and lower 5-year 
OS [33, 45].
Problems related to early diagnostics of tumors are 
well recognized worldwide based on statistical data 
analysis, we suggest that the majority of patients are 
diagnosed with stage IV OSCC which means a worse 
outcome of the disease. Effective measures must 
be taken to ensure OSCC diagnosis at the early stages. 
Supportive evidence on the necessity of neck dissec-
tion as one of the therapeutic modalities (best results 
in RT+SUR group) was found by us.
The incidence of OSCC has grown in the last two 
decades, which, at least partly, may be explained 
by a contributive role of HPV. HPV positive OSCC has 
a better prognosis than HPV negative; therefore, HPV 
status should be determined for prognostic reasons 
and selection of an appropriate treatment plan. In-
deed, bad habits as smoking and alcohol abuse are 
risk factors that should be included in assessing the 
disease outcome.
The limitation of the study is that it is a retrospec-
tive analysis with a relatively small population. It is also 
difficult to assess the importance of treatment mo-
dalities because some patients treated with RT alone 
presented with an advanced stage of cancer at the time 
of diagnosis and poor general health, furthermore, 
the chemotherapeutical interventions should be pre-
sented by more treatment schemes than cetuximab 
alone. Other studies reporting on similarity in regional 
recurrence rates observed in patients with SCC of the 
tongue when selective and radical neck dissections 
were performed have suggested on supraomohyoid 
neck dissection as a primary treatment for patients 
with clinical N0 tumor [46]. This statement agrees 
with the study results and suggestions, however, our 
study didn’t attempt an assessment of various neck 
dissection types as well as comparison of SUR and 
other treatment modalities.
CONCLUSION
Collectively, the study showed that patients with 
lower T grade, N0 status, lacking bad habits and when 
SUR was applied as one of the treatment modalities 
had better 3 and 5-year OS and DS, and lower HR. Fu-
ture studies leading to more efficient research should 
be undertaken combining tests for HPV validation with 
traditional histopathology methods independently 
performed in several institutions.
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